Research indicates a potential link between COVID-19 and an increased risk of new-onset dementia in adults over 60, with the risk being similar to that from other respiratory infections.
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic | Psychedelic Invest
SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations